Home › Funds › LMR Partners LLP › HALO
LMR Partners LLP position in HALO
HALOZYME THERAPEUTICS INC · Health Care
LMR Partners LLP reported holding 45,000,000 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$65.8M, representing 0.57% of its reported portfolio and ranking #22 among its reported holdings. LMR Partners LLP has disclosed HALO holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How LMR Partners LLP's HALO position evolved
LMR Partners LLP first disclosed a stake in HALO in Q3 2025 at 50,000,000 shares (US$70.5M). Across 4 filings, LMR Partners LLP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 45,000,000 shares valued at US$65.8M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 50.00M | $70.45M | New |
| Q4 2025 | 40.51M | $53.67M | Reduce |
| Q1 2026 | 45.00M | $57.71M | Add |
| Q2 2026 | 45.00M | $65.81M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About HALO and 13F data
HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$196.5M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding HALO
- CONGRESS ASSET MANAGEMENT CO 2.28M sh · $251.89M · Q3 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 2.51M sh · $196.54M · Q2 2026
- SNYDER CAPITAL MANAGEMENT L P 2.40M sh · $187.54M · Q2 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 1.94M sh · $151.69M · Q2 2026
- WASATCH ADVISORS LP 1.05M sh · $115.88M · Q3 2026
- Stephens Investment Management Group LLC 1.39M sh · $109.02M · Q2 2026
- GW&K Investment Management, LLC 1.35M sh · $105.97M · Q2 2026
- Boston Trust Walden Corp 1.08M sh · $84.77M · Q2 2026
- Mizuho Markets Cayman LP 834.50K sh · $65.32M · Q2 2026
More on LMR Partners LLP
FAQ
How long has LMR Partners LLP held HALO?
LMR Partners LLP has disclosed HALO holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is LMR Partners LLP's current position in HALO?
As of Q2 2026, LMR Partners LLP holds 45.00M shares of HALO (HALOZYME THERAPEUTICS INC), valued at $65.81M, representing 0.57% of its reported portfolio and ranking #22.
Has LMR Partners LLP been buying or selling HALO?
In the latest 13F filing (Q2 2026), LMR Partners LLP held unchanged its position in HALO.
Which other funds hold HALO?
Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.